Cat. No. | Product name | CAS No. |
DC1080 |
Tyrphostin 9(AG-17)
Featured
AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431. |
10537-47-0 |
DC12382 |
AG-99
Featured
AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. |
122520-85-8 |
DC9330 |
AIM-100
Featured
AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM IC50 value: 24 nM [3] Target: Ack1 Ack1 inhibitor AIM-100 not only inhibited Ack1 activation but also suppressed AKT tyrosine phosphorylation, leading to cell cycle arrest in the G1 ph |
873305-35-2 |
DC12072 |
Alflutinib (AST2818 mesylate)
Featured
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
2130958-55-1 |
DC11495 |
Allitinib
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
897383-62-9 |
DC11931 |
Alofanib
Featured
Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM |
1612888-66-0 |
DC8072 |
Altiratinib(DCC-2701)
Featured
Altiratinib is a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor in Phase 1 clinical development for the treatment of invasive solid tumors including glioblastoma. |
1345847-93-9 |
DC10209 |
ALW-II-41-27
Featured
ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment. |
1186206-79-0 |
DC7056 |
AMG-208
Featured
AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. |
1002304-34-8 |
DC8845 |
AMG337
Featured
AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays. |
1173699-31-4 |
DC7001 |
AMG-47a
Featured
AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice. |
882663-88-9 |
DC7324 |
Amuvatinib (MP-470)
Featured
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. |
850879-09-3 |
DC8029 |
ANA-12
Featured
ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice. |
219766-25-3 |
DC1020 |
Ponatinib (AP24534)
Featured
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
943319-70-8 |
DC4101 |
Apatinib Mesylate
Featured
Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM. |
1218779-75-9 |
DC10975 |
ARQ-531
Featured
ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, |
2095393-15-8 |
DC8486 |
Varlitinib(ARRY-334543)
ARRY-334543 is a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases. |
845272-21-1 |
DC7359 |
Asp-3026
Featured
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. |
1097917-15-1 |
DC7360 |
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
1050500-29-2 |
DC10921 |
ATH686
Featured
ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase. |
853299-52-2 |
DC8253 |
AV-412(MP-412)
AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. |
451492-95-8 |
DC10009 |
Avitinib free base
Featured
Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
1557267-42-1 |